Brain age as a marker: what a review of interventions does and does not show
This abstract reviews brain-predicted age difference (brain-PAD), the gap between estimated brain age and chronological age. Older-appearing brains were linked to poorer function and higher risk, but intervention evidence is limited; exercise is the clearest proof of concept, and brain-PAD is not yet a validated surrogate endpoint. [1]
Automatic summary · not editorially reviewed
The key findings
Across non-clinical and clinical populations, older-appearing brains were associated with poorer cognitive and physical function and higher mortality risk. [1]
Exercise provides the clearest proof of concept that brain-PAD is potentially modifiable. [1]
Brain-PAD is described as a useful but biologically nonspecific, model-derived biomarker, not a validated surrogate endpoint. [1]
The source at a glance
- Study type / format
- Review (abstract only)
- Population / context
- Non-clinical and clinical populations covered by the reviewed literature; the abstract gives no specific sample sizes.
- Summary based on
- Study abstract
- Original publication
- October 14, 2026
Brain-PAD in healthy and clinical populations
The review asks whether the gap between estimated brain age and chronological age can help judge interventions. Across non-clinical and clinical populations, older-appearing brains were associated with poorer cognitive and physical function, greater physiological burden, higher mortality risk, cardiometabolic vulnerability and various neurological and psychiatric disorders. These are associations, not proof of cause.
Supporting source [1]
Exercise clearest, diet and lifestyle preliminary
The abstract reports that intervention evidence remains limited and heterogeneous. Exercise provides the clearest proof of concept that brain-PAD is potentially modifiable. Dietary interventions and multidomain lifestyle programmes produced suggestive but preliminary evidence. Cognitive, sleep and mind-body interventions yielded sparse or mixed findings. Evidence that medication or neuromodulation reliably normalizes brain-PAD remains inconsistent.
Supporting source [1]
Promising in trials, but not a validated endpoint
In clinical settings, brain-PAD showed promise for predicting disease conversion, disability progression and treatment response, and may support trial stratification, enrichment and monitoring. The authors argue it is a useful but biologically nonspecific, model-derived biomarker. Its interpretation depends on processing choices, harmonization, age-bias correction and longitudinal validity. For now it is best regarded as a complementary biomarker and exploratory outcome, not a validated surrogate endpoint.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. This is a review, so it reports no new primary data. Intervention evidence is described as limited and heterogeneous, and brain-PAD is not a validated surrogate endpoint.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Luo Y, Cole JH, Lu H. · europepmc.org · October 14, 2026